Safety and Efficacy of Kygevvi in Thymidine Kinase 2 Deficiency @checkrare
Safety and Efficacy of Kygevvi in Thymidine Kinase 2 Deficiency  @checkrare
Uploaded August 2026 | Updated November 2026, 3 days ago
Caterina Garone, PhD, MD, Associate Professor at the University of Bologna, discusses the summary of safety and efficacy data on Kygevvi (doxecitine and doxribtimine) in patients with thymidine kinase 2 deficiency (TK2d).

TK2d is a rare genetic disease characterized by progressive and severe muscle weakness. It is often fatal. Patients who develop symptoms before the age of 12 years tend to show rapid disease progression and are at high risk of premature death. Other common symptoms include breathing difficulties, weakness in the eye muscles, and trouble chewing and swallowing. TK2d is caused by genetic mutations in the TK2 gene.

Kygevvi is a combination of two pyrimidine nucleosides, doxecitine and doxribtimine, that target and restore mitochondrial DNA in the skeletal muscle. It is the first and only treatment, approved by the U.S. Food and Drug Administration (FDA) in November 2025, for patients with TK2d.

New data published in Brain Communications examines the safety and efficacy of Kygevvi in TK2d and highlights the progressive disease burden in untreated patients.

Safety and efficacy data were pooled from retrospective (NCT03701568, NCT05017818) and prospective (NCT03845712) studies and expanded access programs of patients treated with Kygevvi. Untreated patients were pooled from literature reviews and a retrospective chart review study (NCT05017818).

A total of 218 patients were included (104 treated; 114 untreated) and most patients had an age of symptom onset at or before 12 years. In the age-of-symptom-onset-12-years-or-earlier subgroup, restricted mean survival time was 29.2 years over the 30 years after symptom onset for treated patients and 14.4 years for untreated patients.

Loss of 1 or more acquired motor milestones was more frequent before treatment start than after. Substantially more patients regained 1 or more lost motor milestone after treatment start than before. Ventilatory and feeding support were used across all age-of-symptom-onset subgroups, but some patients reduced or discontinued support after starting treatment and fewer patients initiated support after treatment start than before.

Most treatment-emergent adverse events (AEs) did not lead to discontinuation. The most frequent AE was diarrhoea, which was generally mild or moderate and resolved with dose reduction. Serious AEs occurred in 56% of patients and 8% were considered to be drug related. In total, three patients experienced a fatal serious AE, which were not considered to be drug related.

CHAPTERS
Introduction 00:00
Thymidine Kinase 2 Deficiency Overview 1:48
Effect of Kygevvi on Survival 4:52
Importance of Early Diagnosis 7:02
Key Takeaways for Clinicians 9:01
Remaining Challenges 10:25
Safety and Efficacy of Kygevvi in Thymidine Kinase 2 DeficiencyPredicting Treatment Response Outcomes With Proteomic and Machine Learning Analyses in MGDiagnostic Delay in Endocrine DisordersNeuroblastoma: The Children’s Oncology GroupGetting a Rare Disease Drug Approved Is Only Half the Battle | The CheckRare Brief Ep 4Gambling on Clinical TrialsAugust Is SMA Awareness MonthA Patient’s Journey With Essential Thrombocythemia and Polycythemia VeraRare Endocrine Exchange: Why This Conversation MattersNew Stem Cell Method Could Advance Research Into Spinal Muscular AtrophyImprovements in Mobility in Patients Treated with Miv-Cel with Stiff Person SyndromeUCB Study Highlights the Burden of Ocular Myasthenia Gravis
CheckRare |

Safety and Efficacy of Kygevvi in Thymidine Kinase 2 Deficiency

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER